Physician profile
John E Unison
NPI 1972598951
$1,007.57
in general payments reported to CMS, 2019-2025
20 companies · $91.44 in 2025
The $91.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2021: $18.22 · 2022: $24.02 · 2023: $28.28 · 2024: $79.24 · 2025: $91.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $313.72 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $133.74 | 2019-2021 | |
| Allergan, INC. | $114.30 | 2019 | |
| Amgen INC. | $61.11 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $54.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.51 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.49 | 2019 | |
| Shire North American Group INC | $35.77 | 2019 | |
| Abbott Laboratories | $32.63 | 2025 | Cardiomems |
| Glaxosmithkline, LLC. | $26.34 | 2022-2023 | Arexvy |
| Supernus Pharmaceuticals, INC. | $21.85 | 2019 | |
| Neos Therapeutics, Lp | $21.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.63 | 2019 | |
| Sanofi Pasteur INC. | $17.14 | 2024 | |
| Dermira, INC. | $14.71 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $12.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.78 | 2019 | |
| Pfizer INC. | $11.47 | 2019 | |
| Circassia INC. | $11.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Unison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.